Vallon Pharmaceuticals is a biopharmaceutical company that develops new medications to tackle central nervous system disorders, primarily with a focus on abuse-deterrent medications. Their primary product candidate is ADAIR, an immediate-release dextroamphetamine, that aims to treat ADHD and narcolepsy. With headquarters in Philadelphia, Pennsylvania, and founded in 2018, the company is currently working on developing ADMIR, which is an abuse deterrent formula focused on ADHD treatment.